These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 24814603)

  • 21. Lipid lowering in liver and chronic kidney disease.
    Herrick C; Litvin M; Goldberg AC
    Best Pract Res Clin Endocrinol Metab; 2014 Jun; 28(3):339-52. PubMed ID: 24840263
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lipid-modifying therapy in chronic kidney disease: Pathophysiological and clinical considerations.
    Heine GH; Eller K; Stadler JT; Rogacev KS; Marsche G
    Pharmacol Ther; 2020 Mar; 207():107459. PubMed ID: 31863818
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999.
    Foley RN; Murray AM; Li S; Herzog CA; McBean AM; Eggers PW; Collins AJ
    J Am Soc Nephrol; 2005 Feb; 16(2):489-95. PubMed ID: 15590763
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational study.
    Van Ganse E; Laforest L; Burke T; Phatak H; Souchet T
    Clin Ther; 2007 Aug; 29(8):1671-81. PubMed ID: 17919548
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cardiovascular risk reduction: what do recent trials with rosuvastatin tell us?
    Fabbri G; Maggioni AP
    Adv Ther; 2009 May; 26(5):469-87. PubMed ID: 19444394
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Persistent lipid abnormalities in statin-treated patients with diabetes mellitus in Europe and Canada: results of the Dyslipidaemia International Study.
    Leiter LA; Lundman P; da Silva PM; Drexel H; Jünger C; Gitt AK;
    Diabet Med; 2011 Nov; 28(11):1343-51. PubMed ID: 21679231
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dyslipidemia in Dialysis Patients.
    Qunibi WY
    Semin Dial; 2015; 28(4):345-53. PubMed ID: 25855389
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A randomized, double-blind study of fenofibric acid plus rosuvastatin compared with rosuvastatin alone in stage 3 chronic kidney disease.
    Weinstein DL; Williams LA; Carlson DM; Kelly MT; Burns KM; Setze CM; Lele A; Stolzenbach JC
    Clin Ther; 2013 Aug; 35(8):1186-98. PubMed ID: 23891363
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Managing dyslipidemia in chronic kidney disease.
    Harper CR; Jacobson TA
    J Am Coll Cardiol; 2008 Jun; 51(25):2375-84. PubMed ID: 18565393
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Total lipid management and cardiovascular disease in the dyslipidemia international study.
    Ferrières J; Amber V; Crisan O; Chazelle F; Jünger C; Wood D
    Cardiology; 2013; 125(3):154-63. PubMed ID: 23736147
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Plasma lipoprotein abnormalities in hemodialysis patients--clinical implications and therapeutic guidelines.
    Shoji T; Nishizawa Y
    Ther Apher Dial; 2006 Aug; 10(4):305-15. PubMed ID: 16911182
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Dyslipidemia as a therapeutic target for prevention of cardiovascular events and end-stage renal disease].
    Watanabe T
    Nihon Rinsho; 2008 Sep; 66(9):1761-9. PubMed ID: 18788407
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapeutic practice patterns related to statin potency and ezetimibe/simvastatin combination therapies in lowering LDL-C in patients with high-risk cardiovascular disease.
    Toth PP; Foody JM; Tomassini JE; Sajjan SG; Ramey DR; Neff DR; Tershakovec AM; Hu XH; Tunceli K
    J Clin Lipidol; 2014; 8(1):107-16. PubMed ID: 24528691
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dyslipidaemia in chronic kidney disease.
    Krane V; Wanner C
    Minerva Urol Nefrol; 2007 Sep; 59(3):299-316. PubMed ID: 17912226
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Consensus document for the detection and management of chronic kidney disease].
    Martínez-Castelao A; Górriz JL; Bover J; Segura-de la Morena J; Cebollada J; Escalada J; Esmatjes E; Fácila L; Gamarra J; Gràcia S; Hernández-Moreno J; Llisterri-Caro JL; Mazón P; Montañés R; Morales-Olivas F; Muñoz-Torres M; de Pablos-Velasco P; de Santiago A; Sánchez-Celaya M; Suárez C; Tranche S
    Endocrinol Nutr; 2014 Nov; 61(9):e25-43. PubMed ID: 25171835
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 'Trig-onometry': non-high-density lipoprotein cholesterol as a therapeutic target in dyslipidaemia.
    Jacobson TA
    Int J Clin Pract; 2011 Jan; 65(1):82-101. PubMed ID: 21105969
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lipid lowering in dialysis patients with cardiovascular disease who are awaiting kidney transplantation.
    Aziz F; Garg N; Parajuli S; Djamali A; Stein JH; Mandelbrot D
    Clin Transplant; 2019 Jan; 33(1):e13452. PubMed ID: 30466167
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dyslipidemia in chronic kidney disease: an approach to pathogenesis and treatment.
    Tsimihodimos V; Dounousi E; Siamopoulos KC
    Am J Nephrol; 2008; 28(6):958-73. PubMed ID: 18612199
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Usefulness of statin-ezetimibe combination to reduce the care gap in dyslipidemia management in patients with a high risk of atherosclerotic disease.
    Teoh H; Mendelsohn AA; Goodman SG; Jaffer S; Chen RY; Tjia S; Theriault L; Langer A; Leiter LA;
    Am J Cardiol; 2009 Sep; 104(6):798-804. PubMed ID: 19733714
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lipid-lowering therapy in patients with type 2 diabetes: the case for early intervention.
    Steinmetz A
    Diabetes Metab Res Rev; 2008; 24(4):286-93. PubMed ID: 18273835
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.